Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Gross Margin (2019 - 2025)

Historic Gross Margin for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to 67.84%.

  • Coherus Oncology's Gross Margin rose 129300.0% to 67.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 56.31%, marking a year-over-year increase of 384900.0%. This contributed to the annual value of 55.97% for FY2024, which is 177700.0% up from last year.
  • As of Q3 2025, Coherus Oncology's Gross Margin stood at 67.84%, which was up 129300.0% from 66.89% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Gross Margin registered a high of 90.95% during Q1 2021, and its lowest value of 7.6% during Q4 2023.
  • Over the past 5 years, Coherus Oncology's median Gross Margin value was 66.89% (recorded in 2025), while the average stood at 62.4%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -610800bps in 2023, then surged by 474600bps in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's Gross Margin stood at 83.5% in 2021, then decreased by -18bps to 68.68% in 2022, then tumbled by -89bps to 7.6% in 2023, then surged by 624bps to 55.06% in 2024, then increased by 23bps to 67.84% in 2025.
  • Its Gross Margin was 67.84% in Q3 2025, compared to 66.89% in Q2 2025 and 65.09% in Q1 2025.